FDA Approves rfxcel for Verification Router Service (VRS) Pilot
rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.
The VRS specifications outline interoperability standards that enable a network of VRS providers to meet the 2019 saleable returns requirements of the Drug Quality and Security Act (DSCSA). Working together, the Healthcare Distribution Alliance (HDA) and pharmaceutical stakeholders defined the VRS standards and tested the VRS network to confirm readiness for the upcoming requirements.
rfxcel will work with pharmaceutical supply chain partners of all sizes to extend the testing to ensure that all edge-cases are verified and ensure that interoperability readiness is quantified.
As part the pilot, rfxcel will share the details of its VRS test cases with all VRS providers to ensure they have a common detailed set of test cases. rfxcel will work with the providers to verify the test conditions to enable maximum readiness of the VRS network across all VRS providers.
“We are excited to continue the effort started by the HDA, and we are honored to be approved by the FDA for the VRS pilot,” said rfxcel CEO Glenn Abood. “The pilot seeks to measure and ensure the seamless interoperability between VRS providers across a broad range of use cases. Complete and consistent verification of the use cases is critical to successfully meeting the DSCSA saleable returns requirement.
“We are working with other VRS providers and supply chain partners of all sizes to ensure proper representation in the VRS pilot,” Abood continued. “As a first step, rfxcel will begin sharing our test cases with all VRS providers to set the stage for an open work environment among all participants.”
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance